Wells Fargo on Biogen (BIIB): Price Increases in MS Space Should Offer More Flexibility for BG-12
Tweet Send to a FriendGet Alerts BIIB Hot Sheet
Price: $225.18 -0.74%
Rating Summary:
17 Buy, 8 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 21 | Down: 43 | New: 13
Rating Summary:
17 Buy, 8 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 21 | Down: 43 | New: 13
Trade BIIB Now!
Wells Fargo maintains a 'Market Perform' on Biogen (NASDAQ: BIIB).
Analyst, Brian Abrahams, took note of Novartis' (NYSE: NVS) recent price increase for its MS drugs, Gilenya and Extavia. Now the annual WAC for Gilenya is $57.6K/year, up from $52.4K/year. However, with BIIB's BG-12 hits the market next year, it should benefit because of the planned price of approx. $48K/year...and there will still be room.
Abrahams concluded, "Pricing power clearly remains in the MS space, which is positive for BIIB's existing (Avonex, Tysabri) and future (BG12) products, although we believe high expectations for the MS portfolio, ALS data, and hemophilia program prospects are already baked into the stock's current valuation."
For an analyst ratings summary and ratings history on Biogen click here. For more ratings news on Biogen click here.
Shares of Biogen closed at $145.63 yesterday, with a 52 week range of $83.83-$145.67.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
Analyst, Brian Abrahams, took note of Novartis' (NYSE: NVS) recent price increase for its MS drugs, Gilenya and Extavia. Now the annual WAC for Gilenya is $57.6K/year, up from $52.4K/year. However, with BIIB's BG-12 hits the market next year, it should benefit because of the planned price of approx. $48K/year...and there will still be room.
Abrahams concluded, "Pricing power clearly remains in the MS space, which is positive for BIIB's existing (Avonex, Tysabri) and future (BG12) products, although we believe high expectations for the MS portfolio, ALS data, and hemophilia program prospects are already baked into the stock's current valuation."
For an analyst ratings summary and ratings history on Biogen click here. For more ratings news on Biogen click here.
Shares of Biogen closed at $145.63 yesterday, with a 52 week range of $83.83-$145.67.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
You May Also Be Interested In
- Biogen's (BIIB) BG-12 Data Not Inflated
- UPDATE: Lazard Capital Downgrades Warner Chilcott (WCRX), Says Deal Could Fall Through
- Biogen (BIIB) Weeks-6 TECFIDERA Scripts Continue to Ramp
Create E-mail Alert Related Categories
Analyst CommentsRelated Entities
Raising Prices, Wells Fargo
Login with Facebook
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
